CRDL
Price
$1.06
Change
+$0.10 (+10.42%)
Updated
Jan 16 closing price
Capitalization
106.55M
74 days until earnings call
Intraday BUY SELL Signals
SNOA
Price
$3.29
Change
+$0.02 (+0.61%)
Updated
Jan 16 closing price
Capitalization
5.6M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRDL vs SNOA

Header iconCRDL vs SNOA Comparison
Open Charts CRDL vs SNOABanner chart's image
Cardiol Therapeutics
Price$1.06
Change+$0.10 (+10.42%)
Volume$1.07M
Capitalization106.55M
Sonoma Pharmaceuticals
Price$3.29
Change+$0.02 (+0.61%)
Volume$8.91K
Capitalization5.6M
CRDL vs SNOA Comparison Chart in %
CRDL
Daily Signal:
Gain/Loss:
SNOA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRDL vs. SNOA commentary
Jan 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and SNOA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 17, 2026
Stock price -- (CRDL: $1.06 vs. SNOA: $3.29)
Brand notoriety: CRDL and SNOA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDL: 216% vs. SNOA: 40%
Market capitalization -- CRDL: $106.55M vs. SNOA: $5.6M
CRDL [@Pharmaceuticals: Generic] is valued at $106.55M. SNOA’s [@Pharmaceuticals: Generic] market capitalization is $5.6M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.06B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDL’s FA Score shows that 0 FA rating(s) are green whileSNOA’s FA Score has 0 green FA rating(s).

  • CRDL’s FA Score: 0 green, 5 red.
  • SNOA’s FA Score: 0 green, 5 red.
According to our system of comparison, SNOA is a better buy in the long-term than CRDL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDL’s TA Score shows that 4 TA indicator(s) are bullish while SNOA’s TA Score has 4 bullish TA indicator(s).

  • CRDL’s TA Score: 4 bullish, 4 bearish.
  • SNOA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CRDL is a better buy in the short-term than SNOA.

Price Growth

CRDL (@Pharmaceuticals: Generic) experienced а +6.29% price change this week, while SNOA (@Pharmaceuticals: Generic) price change was -9.86% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.04%. For the same industry, the average monthly price growth was +6.33%, and the average quarterly price growth was +18.14%.

Reported Earning Dates

CRDL is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.04% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDL($107M) has a higher market cap than SNOA($5.6M). CRDL YTD gains are higher at: 11.134 vs. SNOA (-9.615). SNOA has higher annual earnings (EBITDA): -2.98M vs. CRDL (-36.15M). CRDL has more cash in the bank: 11.6M vs. SNOA (3.04M). CRDL has less debt than SNOA: CRDL (134K) vs SNOA (535K). SNOA has higher revenues than CRDL: SNOA (16.9M) vs CRDL (0).
CRDLSNOACRDL / SNOA
Capitalization107M5.6M1,912%
EBITDA-36.15M-2.98M1,212%
Gain YTD11.134-9.615-116%
P/E RatioN/AN/A-
Revenue016.9M-
Total Cash11.6M3.04M382%
Total Debt134K535K25%
FUNDAMENTALS RATINGS
CRDL vs SNOA: Fundamental Ratings
CRDL
SNOA
OUTLOOK RATING
1..100
612
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
7862
P/E GROWTH RATING
1..100
10058
SEASONALITY SCORE
1..100
5029

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNOA's Valuation (65) in the Pharmaceuticals Other industry is in the same range as CRDL (68) in the null industry. This means that SNOA’s stock grew similarly to CRDL’s over the last 12 months.

SNOA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that SNOA’s stock grew similarly to CRDL’s over the last 12 months.

SNOA's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that SNOA’s stock grew similarly to CRDL’s over the last 12 months.

SNOA's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as CRDL (78) in the null industry. This means that SNOA’s stock grew similarly to CRDL’s over the last 12 months.

SNOA's P/E Growth Rating (58) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRDL (100) in the null industry. This means that SNOA’s stock grew somewhat faster than CRDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDLSNOA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRDL
Daily Signal:
Gain/Loss:
SNOA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DYN16.700.28
+1.74%
Dyne Therapeutics
SNCR8.70N/A
N/A
Synchronoss Technologies
RKDA2.40N/A
N/A
Arcadia Biosciences
ATI124.35-1.04
-0.83%
ATI
OFIX14.05-0.35
-2.43%
Orthofix Medical

CRDL and

Correlation & Price change

A.I.dvisor tells us that CRDL and EOLS have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDL and EOLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDL
1D Price
Change %
CRDL100%
+10.07%
EOLS - CRDL
31%
Poorly correlated
+4.00%
LNTH - CRDL
31%
Poorly correlated
-1.79%
ACB - CRDL
31%
Poorly correlated
-0.24%
SNOA - CRDL
30%
Poorly correlated
+0.61%
HIMS - CRDL
26%
Poorly correlated
+0.48%
More

SNOA and

Correlation & Price change

A.I.dvisor tells us that SNOA and CRDL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SNOA and CRDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNOA
1D Price
Change %
SNOA100%
+0.61%
CRDL - SNOA
29%
Poorly correlated
+10.07%
BNXTF - SNOA
29%
Poorly correlated
-3.11%
BGLAF - SNOA
27%
Poorly correlated
N/A
AKAN - SNOA
25%
Poorly correlated
-3.05%
CGC - SNOA
24%
Poorly correlated
-2.46%
More